Given that our findings supported treatment with WBRT for several patients in our study, according to the current guidelines (described above), we further analyzed the feasibility of HA-WBRT in ALK-positive NSCLC patients with BM. The gene discussed is ALK; the disease is non-small cell lung carcinoma.